Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th congress of european crohn's and colitis organization (ecco)

Paris, france / accesswire / february 13, 2024 / abivax sa (euronext paris:abvx))(nasdaq:abvx) ("abivax" or the "company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (uc), will be presented during the 19th congress of the european crohn's and colitis organisation (ecco) on february 21-24, 2024, in stockholm, sweden. "we are delighted that all four submitted abstracts have been accepted for presentations at ecco.
ABVX Ratings Summary
ABVX Quant Ranking